
Opinion|Videos|April 16, 2024
Assessing the Cost-Effectiveness of Prescription Digital Therapeutics
Mahsa Salsabili, PharmD, PhD, underscores the potential cost-effectiveness of treatment through the adoption of prescription digital therapeutics, while acknowledging that additional evidence is required to conclusively determine their cost-effectiveness.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
2
Deborah Dempsey, Pharm.D., MBA, RPh, on 340B discounts vs. rebates | PBMI 2026
3
Navitus launches GLP-1 drug management programs
4
Judi Health, Employers Health team up to launch new PBM solution
5
















